[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346105-105":59,"doc-detail-346105-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","associations-between-glucagon-like-peptide-1-receptor-agonists-glp-1ras-and-cancer-risk-a-systematic-review-and-meta-analysis","Associations Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Cancer Risk - A Systematic Review and Meta-Analysis","","Systematic review and meta-analysis evaluated whether glucagon-like peptide-1 receptor agonist (GLP-1RA) use is associated with cancer incidence. Literature searches in MEDLINE and EMBASE covered publications up to September 17, 2025, including adult studies reporting any cancer incidence outcome. Among 78 observational studies, GLP-1RAs showed statistically significant cancer risk reductions for 10 of 13 obesity-associated cancers, with protective effects versus insulin for selected sites. Thyroid cancer risk was slightly elevated but not statistically significant, emphasizing the need for ongoing monitoring and further large-scale RCT evidence.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/associations-between-glucagon-like-peptide-1-receptor-agonists-glp-1ras-and-cancer-risk-a-systematic-review-and-meta-analysis/346105/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/associations-between-glucagon-like-peptide-1-receptor-agonists-glp-1ras-and-cancer-risk-a-systematic-review-and-meta-analysis/346105.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the main objective of this study?","Question",{"text":113,"@type":114},"To assess the association between GLP-1RA use and cancer incidence through a systematic literature review and meta-analysis.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which cancers showed statistically significant risk reductions with GLP-1RA use?",{"text":118,"@type":114},"GLP-1RA use was associated with statistically significant reductions for 10 of 13 obesity-associated cancers, including colorectal, endometrial, esophageal, gallbladder, liver, ovarian, pancreatic and stomach cancers, plus meningioma and multiple myeloma.",{"name":120,"@type":111,"acceptedAnswer":121},"How did GLP-1RAs compare with insulin regarding cancer risk?",{"text":122,"@type":114},"Compared with insulin, GLP-1RAs provided protective effects for colorectal, liver, and pancreas cancers, based on reported relative risks with 95% confidence intervals.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},346105,1790158921,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","| Associations Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Cancer Risk: A Systematic Review and Meta-Analysis | Cancer Control Volume 33: 1–23 © The Author(s) 2026 Article reuse guidelines:\u003Cbr>[sagepub.com/journals-permissions](sagepub.com/journals-permissions)\u003Cbr>[DOI: 10.1177/10732748261483767](DOI: 10.1177/10732748261483767)\u003Cbr>[journals.sagepub.com/home/ccx](journals.sagepub.com/home/ccx)\u003Cbr>\u003Cbr>|\n| --- | --- |\n| Isha Lalani, BSc1, Reynaldo Nambayan, BSc1, Chantelle Carbonell, BHSc2, Yibing Ruan, PhD3,\u003Cbr>Dylan E. O’Sullivan, PhD2,3,4, Igor Stukalin, MD2,5, Robert J. Hilsden, MD PhD1,4, and Darren R. Brenner, PhD2,4\u003Cbr>Abstract\u003Cbr>Introduction: Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for control of type 2 diabetes and cardiovascular disease (CVD) risk reduction is increasing. Given the established link between obesity and multiple cancers, there is growing interest in the potential effects of GLP-1RAs on cancer risk reduction. This systematic literature review and meta-analysis evaluated the association between GLP-1RA use and cancer incidence. Methods: We conducted literature searches in MEDLINE and EMBASE databases, covering publications up to September 17th, 2025. Our review included studies among adults receiving GLP-1RAs for any indication that reported effects on cancer incidence of any type. Results: Among 1,644 unique citations identified, 139 studies met the inclusion criteria for full-text review. After study exclusion, a total of 78 observational studies were included in the review and meta-analysis. GLP-1RA use was associated with statistically significant reductions in cancer risk for 10 of 13 obesity-associated cancers, specifically colorectal, endometrial, esophageal, gallbladder, liver, ovarian, pancreatic and stomach cancers along with meningioma and multiple myeloma. Compared to insulin specifically, GLP-1RAs provided protective effects against cancer of the colorectum (RR: 0.54, 95% CI: 0.44, 0.66), liver (RR: 0.35, 95% CI: 0.20, 0.62), and pancreas (RR: 0.41, 95% CI: 0.36, 0.48). The risk of developing thyroid cancer was slightly elevated, but not statistically significant, among GLP-1RA users (RR: 1.09, 95% CI: 0.98, 1.21) . Conclusions: Pooled estimates of observational studies suggest notable reductions in cancer incidence for several obesity-associated cancers. As GLP-1RA use increases, ongoing safety monitoring and long-term real-world data are essential. The potential role of GLP-1RAs in cancer risk reduction warrants further investigation through large-scale RCTs, alongside balanced risk-benefit discussions with patients.\u003Cbr>Keywords\u003Cbr>cancer prevention, cancer risk, glucagon-like peptide-1 receptor agonists (GLP-1RAs), obesity, obesity-associated cancer\u003Cbr>Received: 3 February 2026; Revised: 12 August 2026; Accepted: 14 August 2026 |  |\n| 1Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada 2Department of Oncology, University of Calgary, Calgary, AB, Canada\u003Cbr>3Department of Cancer Epidemiology and Prevention Research, Cancer Care Alberta, Alberta Health Services, Calgary, AB, Canada 4Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada 5Department of Gastroenterology and Hepatology, University of Calgary, Calgary, AB, Canada\u003Cbr>Corresponding author:\u003Cbr>Darren R. Brenner, PhD, Department of Oncology, Cumming School of Medicine, University of Calgary, 3330 Hospital Dr NW, Calgary, AB T2N 4N1, Canada. Email: darren.brenner@ucalgary.ca |  |\n\nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  \nAttribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and","cbCaimPvLcf3fzvR","https://ap.wps.com/l/cbCaimPvLcf3fzvR","pdf",9242858,23,"English","# Abstract\n# Introduction\n# Methods\n# Results\n# Discussion\n# Conclusions","[{\"question\":\"What was the main objective of this study?\",\"answer\":\"To assess the association between GLP-1RA use and cancer incidence through a systematic literature review and meta-analysis.\"},{\"question\":\"Which cancers showed statistically significant risk reductions with GLP-1RA use?\",\"answer\":\"GLP-1RA use was associated with statistically significant reductions for 10 of 13 obesity-associated cancers, including colorectal, endometrial, esophageal, gallbladder, liver, ovarian, pancreatic and stomach cancers, plus meningioma and multiple myeloma.\"},{\"question\":\"How did GLP-1RAs compare with insulin regarding cancer risk?\",\"answer\":\"Compared with insulin, GLP-1RAs provided protective effects for colorectal, liver, and pancreas cancers, based on reported relative risks with 95% confidence intervals.\"}]","Associations Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Cancer Risk - A Systematic Review and Meta-Analysis | PDF",1790060085,58,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73b359cf61eb5efecc3b42a8848e0c83.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f110b0f0c314940831a94aaf7ca5360.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/72defaab4b01264e3ac20c3fb4d0286c.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/47c01168f658b686f33ba1f8b3c7cc51.webp",980,1306]